<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35832078</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1838-7640</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Theranostics</Title><ISOAbbreviation>Theranostics</ISOAbbreviation></Journal><ArticleTitle>Engineering viral genomics and nano-liposomes in microfluidic platforms for patient-specific analysis of SARS-CoV-2 variants.</ArticleTitle><Pagination><StartPage>4779</StartPage><EndPage>4790</EndPage><MedlinePgn>4779-4790</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/thno.72339</ELocationID><Abstract><AbstractText>New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are continuing to spread globally, contributing to the persistence of the COVID-19 pandemic. Increasing resources have been focused on developing vaccines and therapeutics that target the Spike glycoprotein of SARS-CoV-2. Recent advances in microfluidics have the potential to recapitulate viral infection in the organ-specific platforms, known as organ-on-a-chip (OoC), in which binding of SARS-CoV-2 Spike protein to the angiotensin-converting enzyme 2 (ACE2) of the host cells occurs. As the COVID-19 pandemic lingers, there remains an unmet need to screen emerging mutations, to predict viral transmissibility and pathogenicity, and to assess the strength of neutralizing antibodies following vaccination or reinfection. Conventional detection of SARS-CoV-2 variants relies on two-dimensional (2-D) cell culture methods, whereas simulating the micro-environment requires three-dimensional (3-D) systems. To this end, analyzing SARS-CoV-2-mediated pathogenicity via microfluidic platforms minimizes the experimental cost, duration, and optimization needed for animal studies, and obviates the ethical concerns associated with the use of primates. In this context, this review highlights the state-of-the-art strategy to engineer the nano-liposomes that can be conjugated with SARS-CoV-2 Spike mutations or genomic sequences in the microfluidic platforms; thereby, allowing for screening the rising SARS-CoV-2 variants and predicting COVID-19-associated coagulation. Furthermore, introducing viral genomics to the patient-specific blood accelerates the discovery of therapeutic targets in the face of evolving viral variants, including B1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), c.37 (Lambda), and B.1.1.529 (Omicron). Thus, engineering nano-liposomes to encapsulate SARS-CoV-2 viral genomic sequences enables rapid detection of SARS-CoV-2 variants in the long COVID-19 era.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Satta</LastName><ForeName>Sandro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, School of Engineering, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Greater Los Angeles VA Healthcare System, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, School of Medicine, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahabipour</LastName><ForeName>Fahimeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Skin Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Medical Engineering, California Institute of Technology, California, Pasadena, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lentz</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Section of Hematology, Oncology, and Blood &amp; Marrow Transplantation, Department of Medicine, College of Medicine, University of Iowa, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlman</LastName><ForeName>Stanley</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Medicine, University of Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashammakhi</LastName><ForeName>Nureddin</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, Henry Samueli School of Engineering &amp; Applied Science, University of California, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Quantitative Health Science &amp; Engineering and Department of Biomedical Engineering, College of Engineering, Michigan State University, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsiai</LastName><ForeName>Tzung</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Bioengineering, School of Engineering, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Greater Los Angeles VA Healthcare System, Los Angeles, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiology, Department of Medicine, School of Medicine, University of California, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UG3 TR003148</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL129727</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI129269</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI060699</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL111437</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Theranostics</MedlineTA><NlmUniqueID>101552395</NlmUniqueID><ISSNLinking>1838-7640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber><NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="N">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044085" MajorTopicYN="N">Microfluidics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Organ on-a-chip</Keyword><Keyword MajorTopicYN="N">microfluidics</Keyword><Keyword MajorTopicYN="N">mutations, variants of concerns</Keyword><Keyword MajorTopicYN="N">nano-liposomes</Keyword><Keyword MajorTopicYN="N">viral genomics</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>2</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35832078</ArticleId><ArticleId IdType="pmc">PMC9254234</ArticleId><ArticleId IdType="doi">10.7150/thno.72339</ArticleId><ArticleId IdType="pii">thnov12p4779</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA. et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">34111888</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmidt K. New mutations raise specter of 'immune escape'. Science. 2021;371(6527):329&#x2013;30. Epub 2021/01/23.</Citation><ArticleIdList><ArticleId IdType="pubmed">33479129</ArticleId></ArticleIdList></Reference><Reference><Citation>Countries CC-dri. Coronavirus (COVID-19) death rate in countries.</Citation></Reference><Reference><Citation>Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH. et al. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. 2021;596(7871):268&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357629</ArticleId><ArticleId IdType="pubmed">34107529</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatara AM. Role of tissue engineering in COVID-19 and future viral outbreaks. Tissue Eng Part A. 2020;26(9-10):468&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7249458</ArticleId><ArticleId IdType="pubmed">32272857</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Liu J, Xia H, Zhang X, Zou J, Fontes-Garfias CR. et al. BNT162b2-Elicited Neutralization against new SARS-CoV-2 spike variants. N Engl J Med. 2021;385(5):472&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8133696</ArticleId><ArticleId IdType="pubmed">33979486</ArticleId></ArticleIdList></Reference><Reference><Citation>Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592(7852):116&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158177</ArticleId><ArticleId IdType="pubmed">33106671</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4026212</ArticleId><ArticleId IdType="pubmed">24831787</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmer RJ, Russell SJ, Schneider MF. Green tea component EGCG, insulin and IGF-1 promote nuclear efflux of atrophy-associated transcription factor Foxo1 in skeletal muscle fibers. J Nutr Biochem. 2015;26(12):1559&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4679480</ArticleId><ArticleId IdType="pubmed">26344776</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung T. Toxicology for the twenty-first century. Nature. 2009;460(7252):208&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">19587762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashammakhi N, Elkhammas E, Hasan A. Translating advances in organ-on-a-chip technology for supporting organs. J Biomed Mater Res B Appl Biomater. 2019;107(6):2006&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">30597720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashammakhi N, Darabi MA, Celebi-Saltik B, Tutar R, Hartel MC, Lee J, Microphysiological systems: next generation systems for assessing toxicity and therapeutic effects of nanomaterials. Small Methods. 2020. 4(1). Epub 2020/10/13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546538</ArticleId><ArticleId IdType="pubmed">33043130</ArticleId></ArticleIdList></Reference><Reference><Citation>Villenave R, Wales SQ, Hamkins-Indik T, Papafragkou E, Weaver JC, Ferrante TC. et al. Human gut-on-a-chip supports polarized infection of coxsackie B1 virus in vitro. PLoS One. 2017;12(2):e0169412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5287454</ArticleId><ArticleId IdType="pubmed">28146569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-chip: a fast track for engineered human tissues in drug development. Cell Stem Cell. 2018;22(3):310&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837068</ArticleId><ArticleId IdType="pubmed">29499151</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">25093883</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashammakhi N, Wesseling-Perry K, Hasan A, Elkhammas E, Zhang YS. Kidney-on-a-chip: untapped opportunities. Kidney Int. 2018;94(6):1073&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6408139</ArticleId><ArticleId IdType="pubmed">30366681</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls AC, Tortorici MA, Frenz B, Snijder J, Li W, Rey FA. et al. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol. 2016;23(10):899&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5515730</ArticleId><ArticleId IdType="pubmed">27617430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bein A, Shin W, Jalili-Firoozinezhad S, Park MH, Sontheimer-Phelps A, Tovaglieri A. et al. Microfluidic organ-on-a-chip models of human intestine. Cell Mol Gastroenterol Hepatol. 2018;5(4):659&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5924739</ArticleId><ArticleId IdType="pubmed">29713674</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashammakhi N, Nasiri R, Barros NR, Tebon P, Thakor J, Goudie M. et al. Gut-on-a-chip: current progress and future opportunities. Biomaterials. 2020;255:120196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7396314</ArticleId><ArticleId IdType="pubmed">32623181</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertas YN, Mahmoodi M, Shahabipour F, Jahed V, Diltemiz SE, Tutar R. et al. Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19) Emergent Mater. 2021;4(1):35&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962632</ArticleId><ArticleId IdType="pubmed">33748672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bristow MR, Zisman LS, Altman NL, Gilbert EM, Lowes BD, Minobe WA. et al. Dynamic regulation of SARS-CoV-2 binding and cell entry mechanisms in remodeled human ventricular myocardium. JACC Basic Transl Sci. 2020;5(9):871&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314447</ArticleId><ArticleId IdType="pubmed">32838074</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang H, Abouleila Y, Si L, Ortega-Prieto AM, Mummery CL, Ingber DE. et al. Human organs-on-chips for virology. Trends Microbiol. 2020;28(11):934&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357975</ArticleId><ArticleId IdType="pubmed">32674988</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C. et al. Structural basis for neutralization of SARS-CoV-2 by a potent therapeutic antibody. Science. 2020;369(6510):1505&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402622</ArticleId><ArticleId IdType="pubmed">32703908</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015-2016. NCHS Data Brief. 2017(288):1-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29155689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202686</ArticleId><ArticleId IdType="pubmed">32376603</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C. et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A. 2015;112(33):10473&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4547275</ArticleId><ArticleId IdType="pubmed">26216974</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017;114(35):E7348&#x2013;E57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584442</ArticleId><ArticleId IdType="pubmed">28807998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadden TA, Tsai AG. Addressing disparities in the management of obesity in primary care settings. N Engl J Med. 2020;383(10):977&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32877588</ArticleId></ArticleIdList></Reference><Reference><Citation>ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1483912</ArticleId><ArticleId IdType="pubmed">16796401</ArticleId></ArticleIdList></Reference><Reference><Citation>Enjuanes L, Zuniga S, Castano-Rodriguez C, Gutierrez-Alvarez J, Canton J, Sola I. Molecular basis of coronavirus virulence and vaccine development. Adv Virus Res. 2016;96:245&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112271</ArticleId><ArticleId IdType="pubmed">27712626</ArticleId></ArticleIdList></Reference><Reference><Citation>Poudel S, Ishak A, Perez-Fernandez J, Garcia E, Leon-Figueroa DA, Romani L. et al. Highly mutated SARS-CoV-2 omicron variant sparks significant concern among global experts - what is known so far? Travel Med Infect Dis. 2022;45:102234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8666662</ArticleId><ArticleId IdType="pubmed">34896326</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Chen J, Gao K, Hozumi Y, Yin C, Wei GW. Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants. Commun Biol. 2021;4(1):228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884689</ArticleId><ArticleId IdType="pubmed">33589648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa J, Zhu W, Tonnu N, Singer O, Hunter T, Ryan AL, The D614G mutation in the SARS-CoV-2 spike protein increases infectivity in an ACE2 receptor dependent manner. bioRxiv. 2020.</Citation></Reference><Reference><Citation>Kim SM, Lee SH, Suh KY. Cell research with physically modified microfluidic channels: a review. Lab Chip. 2008;8(7):1015&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">18584072</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan Q, Macaraniag C, Zhou J, Papautsky I. Microfluidic systems for hydrodynamic trapping of cells and clusters. Biomicrofluidics. 2020;14(3):031502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8719525</ArticleId><ArticleId IdType="pubmed">34992704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashkin A, Dziedzic JM, Bjorkholm JE, Chu S. Observation of a single-beam gradient force optical trap for dielectric particles. Opt Lett. 1986;11(5):288.</Citation><ArticleIdList><ArticleId IdType="pubmed">19730608</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo F, Li S, Caglar MU, Mao Z, Liu W, Woodman A. et al. Single-cell virology: on-chip investigation of viral infection dynamics. Cell Rep. 2017;21(6):1692&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5689460</ArticleId><ArticleId IdType="pubmed">29117571</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159286</ArticleId><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Wang P, Luo R, Wang Y, Li Z, Guo Y, Biomimetic human disease model of SARS-CoV-2 induced lung injury and immune responses on organ chip system. Adv Sci (Weinh). 2020:2002928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7646023</ArticleId><ArticleId IdType="pubmed">33173719</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun AM, Hoffman T, Luu BQ, Ashammakhi N, Li S. Application of lung microphysiological systems to COVID-19 modeling and drug discovery: a review. Biodes Manuf. 2021. pp. 1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213042</ArticleId><ArticleId IdType="pubmed">34178414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Liu J, Wang X, Feng L, Wu J, Zhu X. et al. Organ-on-a-chip: recent breakthroughs and future prospects. Biomed Eng Online. 2020;19(1):9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7017614</ArticleId><ArticleId IdType="pubmed">32050989</ArticleId></ArticleIdList></Reference><Reference><Citation>Longlong Si HB, Melissa Rodas, Wuji Cao, Crystal Yuri Oh, Amanda Jiang, Rasmus Moller, Human organ chip-enabled pipeline to rapidly repurpose therapeutics during viral pandemics. August 19. 2020.</Citation></Reference><Reference><Citation>Lehmann M, Allers K, Heldt C, Meinhardt J, Schmidt F, Rodriguez-Sillke Y. et al. Human small intestinal infection by SARS-CoV-2 is characterized by a mucosal infiltration with activated CD8(+) T cells. Mucosal Immunol. 2021;14(6):1381&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8379580</ArticleId><ArticleId IdType="pubmed">34420043</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar D, Mohanty A. Gut microbiota and COVID-19 possible link and implications. Virus Res. 2020;285:198018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217790</ArticleId><ArticleId IdType="pubmed">32430279</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y, Luo R, Wang Y, Deng P, Song T, Zhang M. et al. SARS-CoV-2 induced intestinal responses with a biomimetic human gut-on-chip. Sci Bull (Beijing) 2021;66(8):783&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7704334</ArticleId><ArticleId IdType="pubmed">33282445</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho A, Alqusairi R, Adams A, Paul M, Kothari N, Peters S. et al. SARS-CoV-2 gastrointestinal infection causing hemorrhagic colitis: implications for detection and transmission of COVID-19 disease. Am J Gastroenterol. 2020;115(6):942&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7172485</ArticleId><ArticleId IdType="pubmed">32496741</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7305763</ArticleId><ArticleId IdType="pubmed">32788101</ArticleId></ArticleIdList></Reference><Reference><Citation>Loo J, Spittle DA, Newnham M. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021;76(4):412&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">33408195</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbig BA, Yu X, Diamond SL. Using microfluidic devices to study thrombosis in pathological blood flows. Biomicrofluidics. 2018;12(4):042201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5953752</ArticleId><ArticleId IdType="pubmed">29861812</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumm ZA, Lloyd GM, Francis CP, Nasif LH, Mitchell DA, Golde TE. et al. Precision therapeutic targets for COVID-19. Virol J. 2021;18(1):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8006140</ArticleId><ArticleId IdType="pubmed">33781287</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(22):2124&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa PF, Albers HJ, Linssen JEA, Middelkamp HHT, van der Hout L, Passier R. et al. Mimicking arterial thrombosis in a 3D-printed microfluidic in vitro vascular model based on computed tomography angiography data. Lab Chip. 2017;17(16):2785&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">28717801</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Neelamegham S. Application of microfluidic devices in studies of thrombosis and hemostasis. Platelets. 2017;28(5):434&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5819608</ArticleId><ArticleId IdType="pubmed">28580870</ArticleId></ArticleIdList></Reference><Reference><Citation>Branchford BR, Ng CJ, Neeves KB, Di Paola J. Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis. Thromb Res. 2015;136(1):13&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910695</ArticleId><ArticleId IdType="pubmed">26014643</ArticleId></ArticleIdList></Reference><Reference><Citation>McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386875</ArticleId><ArticleId IdType="pubmed">32586214</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C. et al. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol. 2020;11:584241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7593765</ArticleId><ArticleId IdType="pubmed">33178218</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazzaruso C, Mariani G, Ravetto C, Malinverni L, Tondelli E, Cerrone M. et al. Lupus anticoagulant and mortality in patients hospitalized for COVID-19. J Thromb Thrombolysis. 2021;52(1):85&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648549</ArticleId><ArticleId IdType="pubmed">33159639</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan Ali O, Bomze D, Risch L, Brugger SD, Paprotny M, Weber M. et al. Severe coronavirus disease 2019 (COVID-19) is associated with elevated serum immunoglobulin (Ig) a and antiphospholipid IgA antibodies. Clin Infect Dis. 2021;73(9):e2869&#x2013;e74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543315</ArticleId><ArticleId IdType="pubmed">32997739</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese KMJ, Linskens EA, Benoit D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost. 2020;18(9):2191&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361253</ArticleId><ArticleId IdType="pubmed">32619328</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP. et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med. 2020;383(3):288&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217555</ArticleId><ArticleId IdType="pubmed">32369280</ArticleId></ArticleIdList></Reference><Reference><Citation>Whyte CS, Morrow GB, Mitchell JL, Chowdary P, Mutch NJ. Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19. J Thromb Haemost. 2020;18(7):1548&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264738</ArticleId><ArticleId IdType="pubmed">32329246</ArticleId></ArticleIdList></Reference><Reference><Citation>Harzallah I, Debliquis A, Drenou B. Lupus anticoagulant is frequent in patients with COVID-19. J Thromb Haemost. 2020;18(8):2064&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7264773</ArticleId><ArticleId IdType="pubmed">32324958</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant VJ. Doctor-patient communication: a five year training programme for medical students. N Z Med J. 1988;101(848):424&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">3393334</ArticleId></ArticleIdList></Reference><Reference><Citation>Roncon L, Zuin M, Barco S, Valerio L, Zuliani G, Zonzin P. et al. Incidence of acute pulmonary embolism in COVID-19 patients: systematic review and meta-analysis. Eur J Intern Med. 2020;82:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498252</ArticleId><ArticleId IdType="pubmed">32958372</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M, Rigatelli G, Zuliani G, Roncon L. The risk of thrombosis after acute-COVID-19 infection. QJM. 2021;114(9):619&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7989150</ArticleId><ArticleId IdType="pubmed">33720351</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobaiqy M, MacLure K, Elkout H, Stewart D. Thrombotic adverse events reported for moderna, pfizer and oxford-astrazeneca COVID-19 vaccines: comparison of occurrence and clinical outcomes in the eudravigilance database. Vaccines (Basel) 2021. 9(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8624459</ArticleId><ArticleId IdType="pubmed">34835256</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam A, Bashir MS, Joyce K, Rashid H, Laher I, Elshazly S. An update on COVID-19 vaccine induced thrombotic thrombocytopenia syndrome and some management recommendations. Molecules. 2021. 26(16)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8400504</ArticleId><ArticleId IdType="pubmed">34443589</ArticleId></ArticleIdList></Reference><Reference><Citation>Sessa M, Kragholm K, Hviid A, Andersen M. Thromboembolic events in younger women exposed to pfizer-biontech or moderna COVID-19 vaccines. Expert Opin Drug Saf. 2021;20(11):1451&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8330010</ArticleId><ArticleId IdType="pubmed">34264151</ArticleId></ArticleIdList></Reference><Reference><Citation>Merchant HA. COVID vaccines and thrombotic events: EMA issued warning to patients and healthcare professionals. J Pharm Policy Pract. 2021;14(1):32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7988638</ArticleId><ArticleId IdType="pubmed">33761987</ArticleId></ArticleIdList></Reference><Reference><Citation>Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med. 2021;16(3):803&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7940863</ArticleId><ArticleId IdType="pubmed">33687691</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD. et al. Thrombocytopenia following pfizer and moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96(5):534&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014568</ArticleId><ArticleId IdType="pubmed">33606296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, Khunti K. et al. Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. BMJ. 2021;374:n1931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8388189</ArticleId><ArticleId IdType="pubmed">34446426</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie KL, Cushman M, Elkind MSV, Lyden PD, Saposnik G, American heart association/american stroke association stroke council l. diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. Stroke. 2021;52(7):2478&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">33914590</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker RC. COVID-19 update: COVID-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7225095</ArticleId><ArticleId IdType="pubmed">32415579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko N, Satta S, Komuro Y, Muthukrishnan SD, Kakarla V, Guo L. et al. Flow-mediated susceptibility and molecular response of cerebral endothelia to SARS-CoV-2 infection. Stroke. 2021;52(1):260&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7769899</ArticleId><ArticleId IdType="pubmed">33161843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Xiang L, Lin F, Cai Z, Ruan H, Wang J. et al. Inhaled ACE2-engineered microfluidic microsphere for intratracheal neutralization of COVID-19 and calming of the cytokine storm. Matter. 2022;5(1):336&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8524658</ArticleId><ArticleId IdType="pubmed">34693277</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandro Satta ZM, Rebecca Hernandez, Susana Cavallero, Tong Zhou, Tzung K. Hsiai, and Changcheng Zhou. An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 spike protein-induced inflammation in both murine and human macrophages Theranostics. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8965482</ArticleId><ArticleId IdType="pubmed">35401811</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M, Laddomada T, Ranucci M, Baryshnikova E. Blood viscosity during coagulation at different shear rates. Physiol Rep. 2014. 2(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4187573</ArticleId><ArticleId IdType="pubmed">24994896</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res. 2003;60(1):26&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">14522404</ArticleId></ArticleIdList></Reference><Reference><Citation>Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G. Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol. 2021;17(1):46&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7570423</ArticleId><ArticleId IdType="pubmed">33077917</ArticleId></ArticleIdList></Reference><Reference><Citation>Jigar Panchal H, Kent NJ, Knox AJS, Harris LF. Microfluidics in haemostasis: a review. molecules. 2020. 25(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070452</ArticleId><ArticleId IdType="pubmed">32075008</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Han D, Pauletti GM, Steckl AJ. Blood coagulation screening using a paper-based microfluidic lateral flow device. Lab Chip. 2014;14(20):4035&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">25144164</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanna V, Satta S, Hsiai T, Sechi M. Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition. Eur J Med Chem. 2022;231:114121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8755562</ArticleId><ArticleId IdType="pubmed">35114539</ArticleId></ArticleIdList></Reference><Reference><Citation>Satta S, Lai A, Cavallero S, Williamson C, Chen J, Blazquez-Medela AM. et al. Rapid detection and inhibition of SARS-CoV-2-spike mutation-mediated microthrombosis. Adv Sci (Weinh) 2021;8(23):e2103266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646611</ArticleId><ArticleId IdType="pubmed">34687279</ArticleId></ArticleIdList></Reference><Reference><Citation>Satta S, Meng Z, Hernandez R, Cavallero S, Zhou T, Hsiai TK. et al. An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages. Theranostics. 2022;12(6):2639&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8965482</ArticleId><ArticleId IdType="pubmed">35401811</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R, Charron J, Stenger CL, Painter J, Steward H, Cook TW, SARS-CoV-2 (COVID-19) structural/evolution dynamicome: insights into functional evolution and human genomics. bioRxiv. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7450099</ArticleId><ArticleId IdType="pubmed">32587094</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav R, Chaudhary JK, Jain N, Chaudhary PK, Khanra S, Dhamija P, Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells. 2021. 10(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8067447</ArticleId><ArticleId IdType="pubmed">33917481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Fu B, Yin S, Li Z, Liu H, Zhang H. et al. ORF8 contributes to cytokine storm during SARS-CoV-2 infection by activating IL-17 pathway. iScience. 2021;24(4):102293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7942160</ArticleId><ArticleId IdType="pubmed">33723527</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno Y, Kimura I, Uriu K, Fukushi M, Irie T, Koyanagi Y. et al. SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant. Cell Rep. 2020;32(12):108185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473339</ArticleId><ArticleId IdType="pubmed">32941788</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, Shu T, Wu D, Mu J, Wang C, Huang M. et al. The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Cell Mol Immunol. 2020;17(8):881&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7301057</ArticleId><ArticleId IdType="pubmed">32555321</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A. et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8212749</ArticleId><ArticleId IdType="pubmed">33306235</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Czudnochowski N, Liu Z, Zatta F, Park YJ, Addetia A. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature. 2021;597(7874):97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9282883</ArticleId><ArticleId IdType="pubmed">34261126</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasso G, Honig B, Shapira SD. A sweep of earth's virome reveals host-guided viral protein structural mimicry and points to determinants of human disease. Cell Syst. 2021;12(1):82&#x2013;91. e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7552982</ArticleId><ArticleId IdType="pubmed">33053371</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkenbrock JA, Grecco-Machado R, Achenbach S. Arsenal of microfluidic testing devices may combat COVID-19 pandemic. MRS Bull. 2020;45(7):511&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566995</ArticleId><ArticleId IdType="pubmed">33100509</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol. 2022;94(4):1641&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">34914115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey J, Balls M. Recent efforts to elucidate the scientific validity of animal-based drug tests by the pharmaceutical industry, pro-testing lobby groups, and animal welfare organisations. BMC Med Ethics. 2019;20(1):16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6397470</ArticleId><ArticleId IdType="pubmed">30823899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3902221</ArticleId><ArticleId IdType="pubmed">24489990</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui P, Wang S. Application of microfluidic chip technology in pharmaceutical analysis: a review. J Pharm Anal. 2019;9(4):238&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6704040</ArticleId><ArticleId IdType="pubmed">31452961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bein A, Kim S, Goyal G, Cao W, Fadel C, Naziripour A. et al. Enteric coronavirus infection and treatment modeled with an immunocompetent human intestine-on-a-chip. Front Pharmacol. 2021;12:718484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8573067</ArticleId><ArticleId IdType="pubmed">34759819</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Zhang YS, Zhang X, Liu C. Organ-on-a-chip platforms for accelerating the evaluation of nanomedicine. Bioact Mater. 2021;6(4):1012&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566214</ArticleId><ArticleId IdType="pubmed">33102943</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YS, Aleman J, Shin SR, Kilic T, Kim D, Mousavi Shaegh SA. et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci U S A. 2017;114(12):E2293&#x2013;E302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5373350</ArticleId><ArticleId IdType="pubmed">28265064</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu N, Wang J, Zhang ZF, Pang DW, Wang HZ, Zhang ZL. Anisotropic cell-to-cell spread of vaccinia virus on microgrooved substrate. Biomaterials. 2014;35(19):5049&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">24685266</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>